Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513848 · ClinicalTrials.gov registry record · NA
Morning Light Treatment at Home to Reduce PTSD Symptoms
A NA study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT03513848 is a NA study that has completed, run by Rush University Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT03513848, a NA study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
There is evidence that some of the circadian photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), project directly to the amygdala, an area of the brain implicated in PTSD. Thus, a self-administered morning light treatment at home (shifts clock earlier and stimulates ipRGCs) may be a potentially efficacious adjunctive strategy for reducing PTSD symptoms. This study will test a 4 week daily 1 hour morning light treatment (active vs placebo) in individuals with PTSD. Outcome measures include measures of PTSD and depression.
Interventions
- DEVICE Retimer
- DEVICE Retimer placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2018-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03513848
The ClinicalTrials.gov registry entry for NCT03513848 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Retimer is the first listed.
NCT03513848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03513848 about?
NCT03513848 is a clinical study titled "Morning Light Treatment at Home to Reduce PTSD Symptoms". There is evidence that some of the circadian photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), project directly to the amygdala, an area of the brain implicated in PTSD. Thus, a self-administered morning light treatment at home (shifts clock earlier and stimulates ipR...
What is the current status of trial NCT03513848?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-04-01. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT03513848?
The interventions under investigation include: Retimer (DEVICE), Retimer placebo (DEVICE).
Who is sponsoring clinical trial NCT03513848?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.